RMC No. 113-2022 updates the VAT-exempt medicines list under the CREATE Act, correcting and deleting certain COVID-19 treatments, effective July 1, 2022. Businesses must adjust VAT filings accordingly.

Businesses dealing with pharmaceutical sales must immediately review their VAT compliance for medicines prescribed for COVID-19. Recent updates endorsed by the Food and Drug Administration now correct and delete certain medicines from the VAT-exempt list under Republic Act No. 11534, the CREATE Act. This affects manufacturers, distributors, retailers, and healthcare providers supplying these medicines.

What Changed

Revenue Memorandum Circular No. 113-2022 publishes the July 1, 2022 letter from FDA OIC-Director General Oscar G. Gutierrez, Jr., which updates the


Leave a Comment

Your email address will not be published. Required fields are marked *